Optimizing G-CSF Use with SG

In clinical practice, the approach to G-CSF use with sacituzumab govitecan (SG) is typically individualized based on patient-specific risk factors and prior tolerance. Many clinicians reserve primary prophylaxis for patients at higher risk for neutropenia—such as those with significant comorbidities, extensive prior therapy, or baseline cytopenias—while others use secondary prophylaxis after an initial neutropenic event. Risk assessment remains central, balancing efficacy, toxicity, and patient convenience. When choosing between pegfilgrastim and filgrastim for patients receiving SG on a Day 1 and Day 8 schedule, providers often consider logistics and timing. Ultimately, practice patterns vary, but supportive care is tailored to minimize treatment interruptions and maintain dose intensity.